Business Wire

NJ-SOLIDIA-TECHNOLOGIES

15.10.2020 15:02:08 CEST | Business Wire | Press release

Share
Solidia Technologies Announces Possibility of Turning Concrete into a Carbon Sink for the Planet

Solidia Technologies® CEO Tom Schuler shared the possibility of turning Solidia Concrete into a carbon sink for the planet during his TED Talk at TED and Future Stewards’ Global Countdown Launch. Tom was invited to "The Countdown," a call to action on climate change, to explain how cement and concrete contribute to the global carbon challenge and the potential impact of new production technologies for Solidia Cement™ and Solidia Concrete™.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201015005299/en/

"To address global warming, innovation in both cement production and carbon utilization are absolutely essential," said Tom. "Our new technology for ready-mix concrete is currently being tested for infrastructure applications. And we have already pushed our research beyond that with a technology that enables concrete to become a carbon sink; that means we consume more carbon dioxide (CO2 ) than we emit during production."

Outlining the issue, he explained how concrete contributes to the global carbon challenge because it is made with cement. "For every ton of cement produced, about a ton of CO2 is released into the atmosphere. As a result, the cement industry is the second largest industrial emitter of CO2 , responsible for about eight percent of global emissions."

By changing the chemistry of cement, Solidia both lowers emissions at the cement plant and consumes CO2 in the production of concrete. "Our cement reacts with CO2 instead of water. During curing, the chemical reaction with our cement breaks apart the CO2 molecules and captures the carbon to make limestone that glues the concrete together.”

For production of precast concrete that is cured in kilns, he explained: “When you combine the emissions reduction during cement production with CO2 consumption during curing, we reduce cement’s carbon footprint by up to 70%.”

Describing the different carbon delivery system developed for ready-mix, he added: "Since we can’t use CO2 gas at a construction site, we had to introduce it into our concrete in solid or liquid form. We are partnering with companies that are turning waste CO2 into a family of chemicals, like oxalic or even citric acid – the same one in orange juice. We use these acids to react with our cement and pack in as much as four times more carbon, resulting in carbon-negative concrete.”

Citing the potential impact, Tom explained: “That means that, in just a few hours, one kilometer of road could permanently consume the same amount of CO2 that nearly 100,000 trees absorb in one year. Thanks to chemistry and waste CO2 , we have the potential to transform concrete – the second most utilized material on the planet – into a carbon sink for the planet.”

About Solidia Technologies®

Based in Piscataway, N.J. (USA), Solidia Technologies® is a cement and concrete technology company that makes it easy and profitable to use CO2 to create superior and sustainable building and construction materials. At scale each year, Solidia can eliminate at least 1.5 gigatonnes of CO₂, save three trillion liters of fresh water, reduce energy consumption equal to ~260 million barrels of oil, and eliminate 100 million tonnes of concrete landfill waste, while engaging industry in a rapid, globally scalable response to some of the greatest threats facing people and planet. Solidia’s investors include Kleiner Perkins , Bright Capital , BASF , BP , Lafarge Holcim , Total Energy Ventures , Oil and Gas Climate Initiative (OGCI) Climate Investments , Air Liquide , Bill Joy and other private investors. Honors include: the 2020, 2019 and 2014 Global Cleantech 100 ; a 2020 and 2014 Best Place to Work in NJ ; 2020, 2019 and 2018 BP Advancing Low Carbon accreditation; the 2019 Solar Impulse 1000 Efficient Solutions ; 2017 ERA Grand Challenge (formerly CCEMC) finalist; 2016 Sustainia 100 ; 2015 NJBiz Business of the Year; 2014 CCEMC Grand Challenge finalist; 2013 R&D Top 100 ; 2013 Katerva Award finalist; and MIT’s Climate CoLab shortlist. Follow Solidia on LinkedIn , Instagram , Twitter , and YouTube .

About TED

TED is a nonprofit organization devoted to Ideas Worth Spreading, often in the form of short talks delivered by leading thinkers and doers. Many of these talks are given at TED conferences, intimate TED Salons and thousands of independently organized TEDx events around the world. Videos of these talks are made available, free, on TED.com and other platforms. Audio versions of TED Talks are published to TED Talks Daily , available on all podcast platforms.

Follow TED on Twitter , Facebook , Instagram and on LinkedIn . Connect at Countdown@ted.com .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release

HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l

BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release

Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye